1-4 of 4
Friedrich Stoelzel, PD, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, MD, Didier Blaise, MD, Emanuele Angelucci, Luca Castagna, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MDPhD, Massimo Martino, Friedrich Stoelzel, PD, MD, Gesine Bug, Yves Chalandon, MD, Benedetto Bruno, MD, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Eolia Brissot, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-140657
Published: 2020
Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Firoozeh Sahebi, Dirk-Jan Eikema, Linda Koster, Nicolaus Kröger, Ellen Meijer, Goda Choi, Montserrat Rovira, Yener Koc, Emanuele Angelucci, Didier Blaise, MD, Corrado Tarella, Andrew McDonald, Concepcion Herrera Arroyo, Noel Milpied, Luca Castagna, Friedrich Stoelzel, PD, MD, Jaime Sanz Caballer, MD PhD, Johanna Tischer, Fabio Ciceri, David Valcarcel, Luigi Rigacci, Patrick J Hayden, MD, Meral Beksac, MD, Ibrahim Yakoub-Agha, Stefan Schonland
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-137789
Published: 2020
Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Nikolas Von Bubnoff, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Eva Maria Wagner, MD, Edouard Forcade, MD PhD, Jaime Sanz Caballer, MD PhD, Domenico Russo, MD, Giovanni Grillo, MD, Tsila Zuckerman, MD, Sinem Civriz Bozdag, MD, Francis A. Ayuk, Friedrich Stoelzel, PD, MD, Sung-Soo Yoon, MD PhD, Jose Valentín García Gutiérrez, MD PhD, David Ritchie, MD ChB, PhD FRACP, FRCPA, Claude-Eric Bulabois, MD, Marie Thérèse Rubio, MD PhD, Judith Xu, Juliane Morando, MD, Bruyère Mahuzier, Pharm D, Satish Mahadevaiah Chandraiah, Gérard Socié, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137603
Published: 2020
Journal Articles

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Sabine Kayser, MD, Jan Moritz Middeke, MD, Michael Kramer, Katja Sockel, MD, Sebastian Stasik, PhD, Regina Herbst, MD, Lars R. Fransecky, MD, Dominik Wolf, Univ. Prof. Dr., Schumacher Martin, MD, Alwin Krämer, MD, Richard Noppeney, MD, Juergen Novotny, MD, Gesine Bug, Katharina S. Götze, Karsten Spiekermann, MD, Matthias Stelljes, MD, Jan-Henrik Mikesch, PD, MD, Marion Subklewe, MD, Antje Schubert, Anke Mütherig, MD, Tilmann Bochtler, MD, Marika Mende, MD, Friedrich Stoelzel, PD, MD, Anne Kubasch, MD, Malte Von Bonin, MD, Mathias Haenel, MD, Ulrich Duehrsen, MD, Johannes Schetelig, MDMSc, Christoph Rollig, MD MSC, Claudia D Baldus, MD, Gerhard Ehninger, MD, Carsten Müller-Tidow, MD, Hubert Serve, MD PhD, Martin Bornhäuser, MD, Uwe Platzbecker, Christian Thiede, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-138427
Published: 2020